{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:30:03Z","timestamp":1791772203090,"version":"4.3.4"},"reference-count":31,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["headachejournal.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Headache"],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To study if galcanezumab is effective for vestibular migraine (VM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There are currently no placebo\u2010controlled trials showing that treatment is effective for VM. Therefore, we performed the first placebo controlled, randomized clinical trial of a calcitonin gene\u2013related peptide\u2013targeted monoclonal antibody for VM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single site, prospective, double\u2010blind placebo controlled randomized clinical trial. Key inclusion criteria were as follows: participants aged 18\u201375\u2009years with a diagnosis of VM or probable VM per Barany Society criteria. The primary outcome was change in VM\u2010PATHI (Vestibular Migraine Patient Assessment Tool and Handicap Inventory) score, and secondary outcomes included change in DHI (Dizziness Handicap Inventory) score, and count of definite dizzy days (DDDs). Participants were randomized 1:1 to 3\u2009months of treatment with galcanezumab or placebo via subcutaneous injection with a pre\u2010filled syringe, 240\u2009mg the first month, and 120\u2009mg for the second and third months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Forty participants were randomized, and 38 participants were in the modified intent to treat analysis. VM\u2010PATHI score was reduced 5.1 points (95% confidence interval [CI] \u221213.0 to 2.7) for placebo (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200921), and 14.8 points (95% CI \u221223.0 to \u22126.5) for galcanezumab (\n                      <jats:italic>N<\/jats:italic>\n                      \u2009=\u200917), a difference of \u22129.6 (95% CI \u221220.7 to 1.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.044). DHI dropped 8.3 points in the placebo arm (95% CI \u221215.0 to 1.6), and 22.0 points in the galcanezumab arm (95% CI \u221231.9 to \u221212.1), a difference of \u221213.7 (95% CI \u221220.4 to \u22128.5,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.018). The count of DDDs per month dropped from 18\u2009days (standard deviation [SD] 7.6) in the baseline month to 12.5\u2009days (SD 11.2) in month 4 for those in the placebo arm, and from 17.9\u2009days (SD 7.9) in the baseline month to 6.6\u2009days (SD 7.3) in month 4 for those in the galcanezumab arm, a difference of \u22125.7\u2009days (95% CI \u221210.7 to \u22120.7,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.026). No serious adverse events were observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this pilot study, galcanezumab was effective in treating VM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/head.14835","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T08:08:28Z","timestamp":1727683708000},"page":"1264-1272","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["A placebo controlled, randomized clinical trial of galcanezumab for vestibular migraine: The\n                    <scp>INVESTMENT<\/scp>\n                    study"],"prefix":"10.1111","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4892-5064","authenticated-orcid":false,"given":"Jeffrey D.","family":"Sharon","sequence":"first","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery University of California, San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roseanne","family":"Krauter","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery University of California, San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5014-9303","authenticated-orcid":false,"given":"Ricky","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery University of California, San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Gardi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery University of California, San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Hum","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2010Head and Neck Surgery University of California, San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Allen","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics University of California, San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morris","family":"Levin","sequence":"additional","affiliation":[{"name":"Department of Neurology University of California, San Francisco  San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000001900"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3233\/VES-2012-0453"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000001024"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000003700"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.3233\/VES-210117"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1044\/2022_AJA-22-00120"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/0003489419845014"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.812678"},{"issue":"4","key":"e_1_2_9_10_1","article-title":"Pharmacological interventions for prophylaxis of vestibular migraine","volume":"2023","author":"Webster K","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"issue":"4","key":"e_1_2_9_11_1","article-title":"Pharmacological interventions for acute attacks of vestibular migraine","volume":"4","author":"Webster KE","year":"2023","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-019-3903-5"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-021-00328-4"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1177\/03331024231161809"},{"key":"e_1_2_9_15_1","doi-asserted-by":"crossref","unstructured":"RahmanSM HauserC FaucherS FineE LuebkeAE.Both systemic calcitonin gene related peptide (CGRP) and a vestibular challenge promote anxiety\u2010related behaviors and dynamic imbalance in mice.bioRxiv. 2023. doi:10.1101\/2023.06.30.547257","DOI":"10.1101\/2023.06.30.547257"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00289"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000002561"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.1990.01870040046011"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-101"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/AUD.0000000000001405"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.25445"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-013-2786-4"},{"issue":"10","key":"e_1_2_9_24_1","first-page":"805","article-title":"Flunarizine in the prophylaxis of vestibular migraine:a randomized controlled trial","volume":"30","author":"Yuan Q","year":"2016","journal-title":"Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.799002"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3390\/medicina59091560"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/0333102417728873"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3336-13.2014"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01145-y"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1459-7"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/00034894211022095"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/MAO.0000000000003886"}],"container-title":["Headache: The Journal of Head and Face Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/head.14835","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T11:54:57Z","timestamp":1762084497000},"score":1,"resource":{"primary":{"URL":"https:\/\/headachejournal.onlinelibrary.wiley.com\/doi\/10.1111\/head.14835"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":31,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/head.14835"],"URL":"https:\/\/doi.org\/10.1111\/head.14835","archive":["Portico"],"relation":{},"ISSN":["0017-8748","1526-4610"],"issn-type":[{"value":"0017-8748","type":"print"},{"value":"1526-4610","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]},"assertion":[{"value":"2024-04-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}